Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial

JAMA. 2017 May 16;317(19):1967-1975. doi: 10.1001/jama.2017.5283.

Abstract

Importance: Synovitis is common and is associated with progression of structural characteristics of knee osteoarthritis. Intra-articular corticosteroids could reduce cartilage damage associated with synovitis but might have adverse effects on cartilage and periarticular bone.

Objective: To determine the effects of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage loss and knee pain.

Design, setting, and participants: Two-year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs saline for symptomatic knee osteoarthritis with ultrasonic features of synovitis in 140 patients. Mixed-effects regression models with a random intercept were used to analyze the longitudinal repeated outcome measures. Patients fulfilling the American College of Rheumatology criteria for symptomatic knee osteoarthritis, Kellgren-Lawrence grades 2 or 3, were enrolled at Tufts Medical Center beginning February 11, 2013; all patients completed the study by January 1, 2015.

Interventions: Intra-articular triamcinolone (n = 70) or saline (n = 70) every 12 weeks for 2 years.

Main outcomes and measures: Annual knee magnetic resonance imaging for quantitative evaluation of cartilage volume (minimal clinically important difference not yet defined), and Western Ontario and McMaster Universities Osteoarthritis index collected every 3 months (Likert pain subscale range, 0 [no pain] to 20 [extreme pain]; minimal clinically important improvement, 3.94).

Results: Among 140 randomized patients (mean age, 58 [SD, 8] years, 75 women [54%]), 119 (85%) completed the study. Intra-articular triamcinolone resulted in significantly greater cartilage volume loss than did saline for a mean change in index compartment cartilage thickness of -0.21 mm vs -0.10 mm (between-group difference, -0.11 mm; 95% CI, -0.20 to -0.03 mm); and no significant difference in pain (-1.2 vs -1.9; between-group difference, -0.6; 95% CI, -1.6 to 0.3). The saline group had 3 treatment-related adverse events compared with 5 in the triamcinolone group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%; 95% CI, -0.5% to -0.007%).

Conclusions and relevance: Among patients with symptomatic knee osteoarthritis, 2 years of intra-articular triamcinolone, compared with intra-articular saline, resulted in significantly greater cartilage volume loss and no significant difference in knee pain. These findings do not support this treatment for patients with symptomatic knee osteoarthritis.

Trial registration: ClinicalTrials.gov Identifier: NCT01230424.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Arthralgia / blood
  • Arthralgia / diagnostic imaging
  • Arthralgia / drug therapy*
  • Cartilage / diagnostic imaging
  • Cartilage / drug effects*
  • Cartilage / pathology
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Glycated Hemoglobin A / metabolism
  • Humans
  • Injections, Intra-Articular
  • Linear Models
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Osteoarthritis, Knee / blood
  • Osteoarthritis, Knee / diagnostic imaging
  • Osteoarthritis, Knee / drug therapy*
  • Outcome Assessment, Health Care
  • Sample Size
  • Sodium Chloride / administration & dosage*
  • Sodium Chloride / adverse effects
  • Synovitis / complications
  • Synovitis / diagnostic imaging
  • Synovitis / drug therapy*
  • Triamcinolone Acetonide / administration & dosage*
  • Triamcinolone Acetonide / adverse effects

Substances

  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human
  • Sodium Chloride
  • Triamcinolone Acetonide

Associated data

  • ClinicalTrials.gov/NCT01230424